HER2-Low Versus HER2-Zero Breast Cancer in the Neoadjuvant Setting: Pathological Complete Response and Exploratory Survival Outcomes in a Single-Center Cohort. - Ateş Ü; Keskinkılıç M; Binnaz Demirkan HM (Medicina (Kaunas, Lithuania), 2026)